Autologous bone marrow transplantation in autoimmune arthritis restores immune homeostasis through CD4+CD25+Foxp3+ regulatory T cells

Blood

Volumn 111, Issue 10, 2008, Pages 5233-5241

  Roord, Sarah T A ^a   De Jager, Wilco ^a   Boon, Louis ^b   Wulffraat, Nico ^a   Martens, Anton ^a   Prakken, Berent ^a,c   Van Wijk, Femke ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b BIOCEROS   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; CD4 ANTIGEN; INTERLEUKIN 2 RECEPTOR ALPHA; PROTEOGLYCAN; TRANSCRIPTION FACTOR FOXP3;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTHRITIS; ARTICLE; AUTOIMMUNE DISEASE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CD4+ CD25+ T LYMPHOCYTE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; HOMEOSTASIS; LEUKOCYTE COUNT; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; RELAPSE; ANIMAL; AUTOTRANSPLANTATION; BAGG ALBINO MOUSE; BONE MARROW TRANSPLANTATION; CD4 LYMPHOCYTE COUNT; HEMOSTASIS; HUMAN; IMMUNE SYSTEM; METHODOLOGY; PHYSIOLOGY; REMISSION; TREATMENT OUTCOME;

ANIMALS; ARTHRITIS; AUTOIMMUNE DISEASES; BONE MARROW TRANSPLANTATION; CD4 LYMPHOCYTE COUNT; FEMALE; HEMOSTASIS; HUMANS; IMMUNE SYSTEM; MICE; MICE, INBRED BALB C; PROTEOGLYCANS; REMISSION INDUCTION; T-LYMPHOCYTES, REGULATORY; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 46749103362     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2007-12-128488     Document Type: Article

References (35)

1. Ilowite NT. Current treatment of juvenile rheumatoid arthritis. Pediatrics. 2002;109:109-115.
2. Onel KB. Advances in the medical treatment of juvenile rheumatoid arthritis. Curr Opin Pediatr. 2000;12:72-75.
3. Wulffraat NM, Kuis W. Treatment of refractory juvenile idiopathic arthritis. J Rheumatol. 2001;28:929-931.
4. Haapasaari J, Kautiainen H, Hannula S, Pohjan-koski H, Hakala M. Good results from combining etanercept to prevailing DMARD therapy in refractory juvenile idiopathic arthritis. Clin Exp Rheumatol. 2002;20:867-870.
5. Kietz DA, Pepmueller PH, Moore TL. Therapeutic use of etanercept in polyarticular course juvenile idiopathic arthritis over a two year period. Ann Rheum Dis. 2002;61:171-173.
6. Lahdenne P, Vahasalo P, Honkanen V. Infliximab or etanercept in the treatment of children with refractory juvenile idiopathic arthritis: an open label study. Ann Rheum Dis. 2003;62:245-247.
7. Lovell DJ, Giannini EH, Reiff A, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis: Pediatric Rheumatology Collaborative Study Group. N Engl J Med. 2000;342:763-769.
8. Lovell DJ, Giannini EH, Reiff A, et al. Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label, extended-treatment trial. Arthritis Rheum. 2003;48:218-226.
9. Quartier P, Taupin P, Bourdeaut F, et al. Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum. 2003;48:1093-1101.
10. Russo RA, Katsicas MM, Zelazko M. Etanercept in systemic juvenile idiopathic arthritis. Clin Exp Rheumatol. 2002;20:723-726.
11. Schmeling H, Mathony K, John V, et al. Acombination of etanercept and methotrexate for the treatment of refractory juvenile idiopathic arthritis: a pilot study. Ann Rheum Dis. 2001;60:410-412.
12. Takei S, Groh D, Bernstein B, et al. Safety and efficacy of high dose etanercept in treatment of juvenile rheumatoid arthritis. J Rheumatol. 2001;28:1677-1680.
13. De K, I, Brinkman DM, Ferster A, et al. Autologous stem cell transplantation for refractory juvenile idiopathic arthritis: analysis of clinical effects, mortality, and transplant related morbidity. Ann Rheum Dis. 2004;63:1318-1326.
14. Wulffraat NM, Sanders LA, Kuis W. Autologous hemopoietic stem-cell transplantation for children with refractory autoimmune disease. Curr Rheumatol Rep. 2000;2:316-323.
15. Sykes M, Nikolic B. Treatment of severe autoimmune disease by stem-cell transplantation. Nature. 2005;435:620-627.
16. Touraine JL, Roncarolo MG, Raudrant D, et al. Induction of transplantation tolerance in humans using fetal cell transplants. Transplant Proc. 2005;37:65-66.
17. Le NT, Chao N. Regulating regulatory T cells. Bone Marrow Transplant. 2007;39:1-9.
18. De K, I, Vastert B, Klein M, et al. Autologous stem cell transplantation for autoimmunity induces immunologic self-tolerance by reprogramming autoreactive T cells and restoring the CD4+CD25+immune regulatory network. Blood. 2006;107:1696-1702.
19. van Bekkum DW. Experimental basis for the treatment of autoimmune diseases with autologous hematopoietic stem cell transplantation. Bone Marrow Transplant. 2003;32(suppl 1):S37-S39.
20. Morgan ME, Flierman R, van Duivenvoorde LM, et al. Effective treatment of collagen-induced arthritis by adoptive transfer of CD25+ regulatory T cells. Arthritis Rheum. 2005;52:2212-2221.
21. Glant TT, Finnegan A, Mikecz K. Proteoglycan-induced arthritis: immune regulation, cellular mechanisms, and genetics. Crit Rev Immunol. 2003;23:199-250.
22. Glant TT, Mikecz K. Proteoglycan aggrecan-induced arthritis: a murine autoimmune model of rheumatoid arthritis. Methods Mol Med. 2004;102:313-338.
23. Glant TT, Cs-Szabo G, Nagase H, Jacobs JJ, Mikecz K. Progressive polyarthritis induced in BALB/c mice by aggrecan from normal and osteoarthritic human cartilage. Arthritis Rheum. 1998;41:1007-1018.
24. Hanyecz A, Berlo SE, Szanto S, et al. Achieve ment of a synergistic adjuvant effect on arthritis induction by activation of innate immunity and forcing the immune response toward the Th1 phenotype. Arthritis Rheum. 2004;50:1665-1676.
25. Bluestone JA, Abbas AK. Natural versus adaptive regulatory T cells. Nat Rev Immunol. 2003;3:253-257.
26. Bach JF, Francois BJ. Regulatory T cells under scrutiny. Nat Rev Immunol. 2003;3:189-198.
27. Bluestone JA, Boehmer H. Regulatory T cells. [Editorial] Semin Immunol. 2006;18:77.
28. Benard A, Ceredig R, Rolink AG. Regulatory T cells control autoimmunity following syngeneic bone marrow transplantation. Eur J Immunol. 2006;36:2324-2335.
29. Feuerer M, Beckhove P, Bai L, et al. Therapy of human tumors in NOD/SCID mice with patient-derived reactivated memory T cells from bone marrow. Nat Med. 2001;7:452-458.
30. Zou L, Barnett B, Safah H, et al. Bone marrow is areservoir for CD4+ CD25+ regulatory T cells that traffic through CXCL12/CXCR4 signals. Cancer Res. 2004;64:8451-8455.
31. Montero E, Nussbaum G, Kaye JF, et al. Regulation of experimental autoimmune encephalomyelitis by CD4+, CD25+ and CD8+ T cells: analysis using depleting antibodies. J Autoimmun. 2004;23:1-7.
32. Zhang X, Koldzic DN, Izikson L, et al. IL-10 is involved in the suppression of experimental autoimmune encephalomyelitis by CD25+ CD4+ regulatory T cells. Int Immunol. 2004;16:249-256.
33. Frey O, Petrow PK, Gajda M, et al. The role of regulatory T cells in antigen-induced arthritis: aggravation of arthritis after depletion and amelioration after transfer of CD4+ CD25+ T cells. Arthritis Res Ther. 2005;7:R291-R301.
34. Stephens LA, Gray D, Anderton SM. CD4+CD25+ regulatory T cells limit the risk of autoimmune disease arising from T cell receptor crossreactivity. Proc Natl Acad Sci U S A. 2005;102:17418-17423.
35. McGeachy MJ, Stephens LA, Anderton SM. Natural recovery and protection from autoimmune encephalomyelitis: contribution of CD4+ CD25+ regulatory cells within the central nervous system. J Immunol. 2005;175:3025-3032.